What Is Considered a Microdose of Tirzepatide: The Working Definition and What It Excludes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Author: FormBlends Editorial

Compliance note

This page provides a definitional answer to a frequently asked question. Microdose tirzepatide is not an FDA-recognized regimen. The numeric ranges described come from patient communities, not clinical guidelines. Discuss any dose with your prescriber.

Key Takeaways

• "Microdose tirzepatide" is a community-coined term with no clinical or regulatory definition; it generally means any weekly dose below the 2.5 mg FDA starting dose
• The working microdose range is 0.5 to 2.5 mg per week, with 1.0 mg as the most commonly described entry point
• The boundary at 2.5 mg is semantic rather than pharmacological because the FDA-labeled starting dose is itself a non-therapeutic titration step
• Below 0.5 mg, doses are sometimes called "sub-microdose" or "test dose," and measurement accuracy with insulin syringes becomes a practical concern
• Microdose initiation is distinct from maintenance step-down; the two terms describe different clinical contexts even when the dose numbers overlap

Direct answer

A microdose of tirzepatide is, by patient-community definition, any weekly dose below 2.5 mg, which is the FDA-approved starting dose. The typical reported range is 0.5 to 2.5 mg per week. The most commonly described entry point is 1.0 mg weekly. The term has no clinical or regulatory definition. Patient communities apply the label inconsistently, and the range is wide enough that two users describing themselves as microdosing may be on doses that differ by a factor of 4. This is a definitional answer to a question with no formal definition. Tirzepatide microdosing is a patient-reported practice, not an FDA-recognized regimen, and the numbers below come from community usage rather than clinical guidance.

Table of contents

1. The working definition
2. What the FDA dose ladder looks like, and where microdoses sit
3. The 2.5 mg boundary and why it is semantic
4. Community consensus around 1.0 mg as the common microdose
5. The wider range: 0.5 to 2.5 mg weekly
6. Sub-microdose: below 0.5 mg weekly
7. Microdose initiation versus maintenance step-down
8. What clinical bodies say about the term
9. How the term is used inconsistently across patient communities
10. The contrary view: is there a more useful threshold
11. FAQ
12. Sources

The working definition

The most usable working definition: a microdose of tirzepatide is any weekly dose below the FDA-approved starting dose of 2.5 mg, used as a sustained regimen rather than as part of a titration ramp. Two conditions matter:

• The dose is below 2.5 mg weekly
• The dose is used sustainably, not as a brief stop on the way to a higher dose

A patient who is at 1.0 mg weekly for two weeks before moving to 2.5 mg is on a personal titration. A patient who is at 1.0 mg weekly for 6 months without titration is microdosing. The definitional difference is intent and duration, not just the number on the syringe.

What the FDA dose ladder looks like, and where microdoses sit

Dose	FDA label status	Patient-community label
15 mg weekly	Maximum maintenance	Maximum / SURMOUNT-1 highest arm
12.5 mg weekly	Maintenance step	High maintenance
10 mg weekly	Maintenance option	Mid-high maintenance
7.5 mg weekly	Intermediate	Intermediate
5 mg weekly	First therapeutic dose	Low therapeutic / SURMOUNT-1 lowest arm
2.5 mg weekly	FDA starting / titration only	FDA starting (not microdose)
2.0 mg weekly	Not FDA-labeled	Upper microdose
1.25 mg weekly	Not FDA-labeled	Common microdose
1.0 mg weekly	Not FDA-labeled	Most common entry microdose
0.5 mg weekly	Not FDA-labeled	Low microdose
Below 0.5 mg	Not FDA-labeled	Sub-microdose / test dose

The clean boundary in this table is 2.5 mg. Everything at 2.5 mg or above is FDA-labeled at a specific titration position. Everything below 2.5 mg is sub-FDA-labeled and falls into the community-defined microdose space.

The 2.5 mg boundary and why it is semantic

One subtle point in the definition: the FDA-approved starting dose of 2.5 mg is itself not a therapeutic dose. The FDA label specifies that 2.5 mg is intended for the first 4 weeks of treatment as a titration step to manage GI side effects before increasing to the first therapeutic dose at 5 mg. SURMOUNT-1, the pivotal weight-loss trial, did not test outcomes at 2.5 mg; its lowest dose arm was 5 mg weekly.

This means the boundary at 2.5 mg between "starting dose" and "microdose" is more semantic than pharmacological. The label says 2.5 mg is for 4 weeks of titration. A patient who stays at 2.5 mg for 6 months is using the dose off-label in a way that overlaps conceptually with microdose practice, even though the dose number itself is on the FDA ladder.

Patient communities reserve "microdose" for sub-2.5 mg doses, which keeps the term distinct from "extended starting dose" or "low-dose maintenance." The distinction is useful for communication, but it does not reflect a sharp pharmacological transition at 2.5 mg.

Community consensus around 1.0 mg as the common microdose

If there is a single most-cited number in tirzepatide microdose discussion, it is 1.0 mg weekly. The reasons:

• Round number, easy to communicate and remember
• 40 percent of the FDA starting dose, a fraction that "feels" sub-therapeutic without being extreme
• At common compounded concentrations (5 mg/mL), 1.0 mg is 0.20 mL or 20 units on an insulin syringe, well within accurate measurement range
• Self-reinforcing community standard: when 1.0 mg becomes the most-cited starting point, new users adopt it because it is the most-cited starting point

The number is not clinically derived. There is no pharmacokinetic or pharmacodynamic threshold at 1.0 mg that distinguishes it from 0.75 mg or 1.25 mg. The 1.0 mg consensus is a social convention.

The wider range: 0.5 to 2.5 mg weekly

Outside the 1.0 mg consensus point, microdose practice spans the 0.5 to 2.5 mg range. Common reported doses across this range:

• 0.5 mg weekly: low microdose, often a starting test dose
• 0.75 mg weekly: low microdose, sometimes used for users with strong reactions
• 1.0 mg weekly: most common entry
• 1.25 mg weekly: explicit "half of FDA starting" reference point
• 1.5 mg weekly: upper microdose, sometimes a titration target
• 2.0 mg weekly: upper microdose, just below FDA starting

The range spans roughly a factor of 4. A 0.5 mg microdose and a 2.0 mg microdose are not pharmacologically similar even though both fit the term. This is one of the reasons the term carries less information than its frequency of use might suggest.

Sub-microdose: below 0.5 mg weekly

Some patient discussions extend the microdose category below 0.5 mg. Reported doses include:

• 0.25 mg weekly: 10 percent of FDA starting; sometimes called a test dose
• 0.1 to 0.2 mg weekly: rarely reported; primarily users with extreme sensitivity to GLP-1 medications

At these doses, measurement accuracy becomes a serious concern. A 0.25 mg dose at 10 mg/mL compounded concentration is 0.025 mL or 2.5 units, below the practical accuracy floor of standard insulin syringes. The dose error margin at these volumes can exceed 50 percent.

There is no clinical evidence base for sub-microdose tirzepatide, and there is no consistent community usage of the term. "Sub-microdose" appears in some discussions and not others. Its presence in this article is descriptive, not prescriptive.

Microdose initiation versus maintenance step-down

One of the most important conceptual distinctions: a patient stepping down from 10 mg standard dose to 1.0 mg for maintenance is not in the same clinical situation as a patient starting at 1.0 mg. The dose number is the same; the clinical context is different.

Step-down for maintenance after standard-dose loss has some clinical acceptance. SURMOUNT-4 demonstrated that continued exposure helps maintain weight loss, although the trial used full doses. Many providers will discuss step-down to lower doses for maintenance even when they would not write a 1.0 mg starting prescription.

Patient communities sometimes use "microdose" for both contexts, which conflates them. The cleaner terminology is "microdose initiation" versus "maintenance step-down." This article uses "microdose" primarily for the initiation context.

What clinical bodies say about the term

The Endocrine Society, the American Association of Clinical Endocrinologists, and the Obesity Society have not defined "microdose" as a clinical term for GLP-1 medications. Their guidelines reference FDA-approved doses and titration schedules. They do not endorse or define sub-FDA-starting dose ranges.

The FDA labels for Mounjaro and Zepbound describe the approved dose range and titration schedule. They do not use or define "microdose."

The compounding pharmacy literature occasionally references low-dose protocols but generally without endorsing specific sub-therapeutic ranges.

The absence of a formal definition from clinical bodies is itself informative. The term is patient-driven, and its working definition reflects community usage rather than expert consensus.

How the term is used inconsistently across patient communities

If you read 100 tirzepatide microdose posts, the dose numbers will span:

• Reddit r/tirzepatidecompound: most commonly 1.0 to 2.0 mg weekly
• Biohacking-focused communities: often 0.5 to 1.5 mg weekly
• Cost-stretching threads: 1.0 to 2.0 mg weekly
• Maintenance step-down discussions: 1.5 to 2.5 mg weekly
• Sub-therapeutic "longevity" communities: 0.25 to 1.0 mg weekly

The same word covers a wide span. Reading any microdose post requires the actual dose number, not just the label, to know what the user is describing.

The contrary view: is there a more useful threshold

One reasonable counter to the "no formal definition" position is that pharmacology might support a more meaningful threshold than the FDA-starting boundary. Possibilities:

• Half the first therapeutic dose: 2.5 mg weekly (half of 5 mg). This would call anything below 2.5 mg a microdose, which is essentially the working definition.
• Receptor occupancy threshold: a dose producing less than some specific percentage of maximal receptor activation. This has not been measured for tirzepatide at sub-therapeutic doses.
• Effect threshold: a dose producing less than some defined weight-loss effect. This requires trial data that does not exist.

The working definition (any dose below FDA starting) is imperfect but defensible. It distinguishes between FDA-labeled use and off-label sub-therapeutic use cleanly. A pharmacologically-derived threshold would be more meaningful but is not currently available.

FAQ

What is considered a microdose of tirzepatide? Any weekly dose below the FDA-approved starting dose of 2.5 mg, used as a sustained regimen. Patient-community definition.

What is the typical range? 0.5 to 2.5 mg weekly, with 1.0 mg as the most common entry point.

Is 2.5 mg a microdose? No. 2.5 mg is the FDA starting dose. Patient communities reserve "microdose" for sub-2.5 mg doses.

Is 1 mg a microdose? Yes, by patient-community definition.

Is 2 mg a microdose? Yes, upper end of the microdose range.

Is there a clinical body that defines microdose? No. The term is patient-driven and not formally defined by clinical organizations.

How low does the term go? Patient reports describe sub-microdoses as low as 0.25 mg weekly. Below 0.5 mg, measurement accuracy becomes a practical concern.

Is maintenance step-down the same as microdose? No. Step-down to lower doses after reaching goal weight is a different clinical context than starting at sub-therapeutic doses.

Why does the range vary so much? Because the term has no agreed clinical threshold and emerged from informal community usage.

What number do most users use? 1.0 mg weekly is the most cited starting point.

Does FDA recognize the term? No. FDA labels describe approved doses and titration schedules and do not use "microdose."

How should I read a microdose post? Always check the actual dose number, not just the label. Two users using the same word may be describing doses that differ by a factor of 4.

Sources

1. FDA Prescribing Information. Mounjaro (tirzepatide). Eli Lilly. Revised 2024.
2. FDA Prescribing Information. Zepbound (tirzepatide). Eli Lilly. Revised 2024.
3. Jastreboff AM et al. SURMOUNT-1 trial. New England Journal of Medicine. 2022.
4. Aronne LJ et al. SURMOUNT-4 maintenance trial. JAMA. 2024.
5. Wadden TA et al. SURMOUNT-3 trial. Nature Medicine. 2023.
6. Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2023.
7. American Association of Clinical Endocrinologists. Obesity Algorithm. 2024.
8. FDA Guidance on Compounding Under Section 503A. 2023.
9. Obesity Society. Pharmacotherapy Position Statement. 2024.
10. FDA Adverse Event Reporting System (FAERS). Public Dashboard. Accessed 2026.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed providers and U.S.-based pharmacies. This article provides definitional information for a patient-reported practice and is not a prescribing recommendation.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions and is not interchangeable with brand-name Mounjaro or Zepbound.

Results Disclaimer. Microdose tirzepatide is not an FDA-recognized regimen. The dose definitions and ranges described come from patient-community usage, not from clinical organizations or regulatory bodies. Individual outcomes vary, and discussion of dose definitions does not imply clinical efficacy.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.